AI Article Synopsis
- - The study identifies the JN.1 variant of SARS-CoV-2 in Morocco through genomic sequencing.
- - Four clinical samples were analyzed, including nasopharyngeal swabs from one female and three male patients.
- - The Illumina COVIDSeq Test was utilized for a thorough genomic analysis of the samples.
Article Abstract
In this study, we report the identification of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) JN.1 variant and the quasi-complete genomic sequencing of four clinical samples in Morocco. Nasopharyngeal swabs were obtained from four patients (one female, three males). The Illumina COVIDSeq Test was used for comprehensive genomic analysis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392428 | PMC |
| http://dx.doi.org/10.1128/mra.00559-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients.
Hum Vaccin Immunother
December 2024
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
The durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-term humoral immunogenicity outcomes after 3 doses of these vaccines. Peripheral blood samples were collected from participants 14-49 days and 155-210 days after administration of the third vaccine dose to assess humoral immune responses through serological assays.
View Article and Find Full Text PDFBackground: A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. However, no clinical data are available regarding critically-ill JN.
View Article and Find Full Text PDFHumoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
Vaccine
September 2024
Faculty of Medical and Health Sciences, Tel-Aviv University, Israel; The Sheba Pandemic Preparedness Research Institute (SPRI), Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.
JN.1, the dominating SARS-CoV-2 variant, is antigenically distinct from ancestral BA.1, BA.
View Article and Find Full Text PDFNeutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Int J Infect Dis
June 2024
Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium; Qualiblood s.a., Research and Development Department, Namur, Belgium; Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France.
Objectives: An increase evasion of the SARS-CoV-2 virus toward vaccination strategies and natural immunity has been rapidly described notably because of the mutations in the spike receptor binding domain and the N-terminal domain.
Methods: Participants of the CRO-VAX HCP study who received the bivalent booster were followed up at 6 months. A pseudovirus-neutralization test was used to assess the neutralization potency of antibodies against D614G, Delta, BA.
Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System.
J Stroke Cerebrovasc Dis
October 2021
nference, inc., One Main Street, Suite 400, East Arcade, Cambridge, MA 02142, USA; nference Labs, 2nd Floor, 22 3rd Cross Rd, Murgesh Pallya, Bengaluru, India. Electronic address:
Objective: To assess the association of COVID-19 vaccines and non-COVID-19 vaccines with cerebral venous sinus thrombosis (CVST).
Materials And Method: We retrospectively analyzed a cohort of 771,805 vaccination events across 266,094 patients in the Mayo Clinic Health System between 01/01/2017 and 03/15/2021. The primary outcome was a positive diagnosis of CVST, identified either by the presence of a corresponding ICD code or by an NLP algorithm which detected positive diagnosis of CVST within free-text clinical notes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!